MAPT and Alzheimer disease: The current biomarker model for AD demonstrated that amyloid biomarkers including CSF Aβ42 level and Aβ PET show abnormality prior to the other biomarkers such as CSF tau level, functional PET scans, and cognitive impairment[3].